Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IgA Monoclonal Gammopathy of Undetermined Significance”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Active Not RecruitingNCT03820817
What this trial is testing

Rifaximin in Patients With Monoclonal Gammopathy

Who this might be right for
IgA Monoclonal GammopathyIgG Monoclonal GammopathyIgM Monoclonal Gammopathy+6 more
Emory University 50
Testing effectiveness (Phase 2)Looking for participantsNCT07209371
What this trial is testing

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

Who this might be right for
IgA Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center 50
Not applicableActive Not RecruitingNCT04023747
What this trial is testing

Oxford Pre-cancerous Lymphoproliferative Disorders Study

Who this might be right for
Pre-cancerous Lymphoproliferative Disorders
University of Oxford 574
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000